Small Molecules

Muvalaplin is a small molecule that reduces Lp(a) formation by binding to the kringle IV domains 7 and 8 of apo(a).¹ This prevents the initial noncovalent interaction between apo(a) and lysine residues in apoB-100, prior to formation of a covalent bond between apo(a) and apoB100 resulting in formation of Lp(a).¹ In a Phase 1 trial, daily administration of muvalaplin resulted in dose-dependent lowering of Lp(a) by up to 65% by day 14 of daily dosing.¹